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Abstract
Background: To explore the relationship between enteroviruses and hospitalized children with hand, foot and
mouth disease (HFMD) complicated with nervous system disease. 234 hospitalized HFMD patients treated in
Shengjing Hospital, Liaoning Province were analyzed retrospectively. Based on the presence and severity of
nervous system disease, the patients were grouped as follows: general patients, severely ill patients, critically ill
patients and fatal patients. Based on the detected pathogen, the patients were grouped as follows: Enterovirus 71
(EV71) infection, coxsackie A16 (CA16) infection and other enterovirus (OE) infection.
Results: Of the 423 hospitalized patients, most were admitted in July 2010(129/423, 30.5%). Enteroviruses were
detected in 177(41.8%). 272/423 patients were male (64.3%), and fatal patients had the greatest proportion of male
patients (p < 0.05). EV71 infection was found in 89/423 patients (21%). CA16 infection was detected in 8/423
patients (16.1%). Compared to group CA16, patients in group EV71 were hospitalized earlier, and the duration of
hospitalization was longer (p < 0.05). Of the 92 patients with nervous system damage, 65 were infected with EV71
and 19 were infected with CA16. Among these CA16 infected patients, 2 had brainstem encephalitis and 1 had
AFP. There were more patients with nervous system dysfunction in group EV71 than in groups CA16 or OE (p <
0.05). The 5 fatalities all occurred in group EV71 patients (p < 0.05). Infection with EV71 was most likely to cause
neurogenic pulmonary edema (p < 0.05). Patients in group EV71 had a higher rate of suffering from coma and
limb movement disorder than patients in groups CA16 or OE (p < 0.05).
Conclusion: The disease progresses faster in EV71-infected HFMD patients. These patients are more likely to suffer
nervous system damage, neurogenic pulmonary edema, severe sequelae or death. CA16 and other enteroviruses
can also cause HFMD with severe nervous system complications.
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Background
Since first reported by Robin Son in 1958 [1], numerous
widespread outbreaks of hand, foot and mouth disease
(HFMD) have occurred in eastern and southeastern
Asia, including Singapore [2], South Korea [3], Malaysia
[4], Japan [5], Vietnam [6], mainland China [7,8] and
Taiwan [9,10]. HFMD was first reported in mainland
China in 1981; since then it has prevailed in most pro-
vinces of China. Nationwide HFMD outbreaks have
occurred in China since 2008, with most of the cases
affecting children ≤ 5 years of age [11]. After this event
HFMD has been made a nationally notifiable disease.
Despite nationwide effort, 1,795,336 cases were diag-
nosed annually in 2010 with 905 deaths. HFDM is a
common infectious disease that can be caused by more
than 20 different enteroviruses, and the symptoms are
generally mild and self-limited. Its main manifestations
are fever, rash and ulcers in areas such as the oral
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mucosa and the hands, feet and buttocks. A small pro-
portion of children patients can experience severe com-
plications, including encephalitis, pneumonia,
myocarditis, brain-stem encephalitis and acute flaccid
paralysis (AFP). High mortality and severe sequelae can
be anticipated when the disease is complicated by neu-
rogenic pulmonary edema, rapid disease progression
[12,13]. HFMD has a disease burden as severe as that
imposed by any other pediatric infectious disease and
has already received considerable attention from all
health sectors at both national and local levels.
Unlike most infectious diseases, it is very difficult to
distinguish between the possible pathogens (Enterovirus
71 and Coxsackie A16) in a clinical context, possibly
because EV71 and CA16 are closely related. Enterovirus
71 (EV71) and coxsackie A16 (CA16) are small, non-
enveloped, positive-stranded RNA viruses that belong to
human enterovirus species A, genus Enterovirus, family
Picornaviridae. Human EV71 and CA16 are two major
pathogens of HFMD in children. These viruses can also
cause many other diseases, many of which manifest as
herpes angina or flu-like symptoms [14]. Together with
CA7 and CA14, these viruses form a distinct genetic
subgroup within cluster A of the genus Enterovirus [15].
Recent studies reported that severe nervous system
damage happened more in patients infected with EV71.
Some reports further suggest that despite the close
genetic relationship between EV71 and CA16, only
EV71 has the potential to cause neurological disease in
acute infection [16,17]; however, we disagree with this
statement. This report summarizes the clinical manifes-
tations of disease and the distribution of pathogens in
HFMD patients, based on patients whose cases were
complicated by nervous system disease.
Results
In 2010, our hospital treated a total of 6,027 cases of
pediatric HFMD. Among these, 423 patients (7.0%) were
hospitalized. Hospital stay lasted from 1 to 101 days
(median 9 days). 78 patients were referred to PICU with
the stay in PICU lasting 1 to 101 days (median 18 days).
The overall patient ages ranged from 3 months to 12.5
years, with an average age of 2.71 years.
Demographic characteristics and clinical manifestations
The 423 patients hospitalized with HFMD were mainly
admitted between May and September. Within that per-
iod, most patients (129/423, 30.5%) were admitted in
July. August and June followed, with 85/423 (20.1%) and
80/423 (18.9%), respectively. Among all admitted
patients, 189/423 (44.7%) were general patients, 197/423
(46.6%) had severe clinical manifestations, 28/423 (6.6%)
were critically ill and 9/423 (2.1%) died. The severely ill,
critically ill and fatal cases were most frequently seen in
June, July and August. July had the greatest number of
severe cases (54/197, 27.4%). The number of critically ill
patients was equally distributed between July and
August (7/28, 25%). An equal number of fatalities
occurred in June and July (3/9, 33.3%). A detailed distri-
bution is shown in Figure 1.
The examination of throat swab and/or stool speci-
mens from these 423 patients revealed the presence of a
viral pathogen in 177 cases (41.84%). Among the 177
patients, there were 85 general patients, 71 severely ill
patients, 16 critically ill patients and 5 deaths. There
was no significant difference in the pathogen detection
rate across groups (p > 0.05). The overall patient ages
ranged from 3 months to 12.5 years, with an average
age of 2.71 years. There were significant differences in
the average ages among the 4 groups (p < 0.05). Among
general, severely ill and critically ill groups, patients who
had experienced more severe symptoms had more little
ages, whereas the group of patients who died showed
less significant difference in age compared to the other
three groups. Male preferences were detected in the
group with severe disease. The proportion of patients
from rural areas was 268/423 (63.3%), but regional dif-
ferences were not apparent among severe cases (p >
0.05). Patients in the group with general disease were
hospitalized later than those in other 3 group t (p <
0.05). The time for patients in the group with critically
disease stayed in hospital was the longest (p < 0.05).
The rate of critically group in term of the number of
patients with white blood cell counts > 12 × 109 in the
initial regular blood test was the highest. Meanwhile
patients with critically disease suffered fever for longer
Figure 1 Distribution of HFMD patients in different months.
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too. In total, 89/423 (21%) EV71 cases were detected,
with a higher detection rate in patients with more severe
manifestations. A total of 68/423 (16.1%) CA16 cases
were detected, with a higher detection rate in patients
less severely affected. Other enteroviruses (20/423, 4.7%)
were also detected, with no significant difference in dis-
tribution among the 4 groups. Patients who had experi-
enced more severe symptoms ended up with worse
outcome (p < 0.05). A detailed distribution of the neuro-
logical sequelae is provided in Table 1.
Data characteristics of the clinical distribution of the
enteroviruses
Samples from the 423 hospitalized HFMD patients were
examined, and 177(41.8%) tested positive for entero-
virus. The results are shown in Figure 2.
Patients with EV71 infection were hospitalized earlier
and for longer periods than those with CA16 infection.
The difference was significant (p < 0.05). Patients with
EV71 infection had the highest average temperature
(39.1°C), which was significantly different from the aver-
age temperatures in the other 2 groups (p < 0.05).
Three critically ill patients had no rash. HFMD was con-
firmed in all patients with EV71 infection, although
there was no significant difference compared to the
other 2 groups (p > 0.05). EV71, CA16 and other enter-
oviruses are all capable of causing nervous system
damage and leading to a certain degree of neurologic
dysfunction. There were 92 patients (52%) with nervous
system damage; the patients with EV71 were especially
at risk (73%). The incidence in the CA16 group was 19
Table 1 Analysis of the clinical data for 423 hospitalized patients
general severely critically fatal p value Total
Case number (n) 189 197 28 9 423
Number of cases in which a pathogen was detected (n) 85(45.0%) 71(36%) 16(57.1%) 5(55.6%) 0.076 177(41.8%)
Age*(Years)① 3.045 ± 2.102 2.546 ± 1.730 1.893 ± 1.397 2.056 ± 1.509 0.003
Gender(male, n) 125(66.1%) 114(57.9%) 25(89.3%) 8(88.9%) 0.003 272(64.3%)
Region(from countryside, n) 116(61.4%) 124(62.9%) 23(82.1%) 5(55.6%) 0.185 268(63.4%)
Time from onset to hospitalization(d)① 4.44 ± 1.37 3.89 ± 1.26 3.92 ± 1.02 3.81 ± 0.96 0.000
Duration of hospitalization(d)② 8.85 ± 2.46 11.63 ± 5.04 49.51 ± 33.20 4.55 ± 1.91 0.000
WBC > 12 × 109 (n) 86(45.5%) 121(61.4%) 27(96.4%) 8(88.9%) 0.000 242(57.2%)
Duration of initial fever(d)② 5.24 ± 1.54 6.33 ± 1.94 8.38 ± 6.42 6.42 ± 2.25 0.012
Highest fever temperature (°C)③ 38.76 ± 0.46 38.846 ± 0.62 39.206 ± 0.51 39.07 ± 0.41 0.032
Hand or foot rash (n) 173(91.5%) 183(92.9%) 23(82.1%) 6(66.7%) 0.017 385(91.0%)
Oral rash (n) 121(64.0%) 118(59.9) 17(74.6) 4(44.4%) 0.608 260(61.5%)
Buttock rash (n) 76(40.2%) 81(41.1%) 6(21.4%) 2(22.2%) 0.159 165(39.0)
No rash (n) 2(7.1%) 1(11.1%) 0.000 3(0.7%)
EV71 (n) 24(12.7%) 47(23.9%) 13(46.4%) 5(55.6%) 0.000 89(21%)
CA16 (n) 49(25.9%) 18(9.1%) 1©(3.6%) 0 0.000 68(16.1%)
Other enteroviruses (n) 12(6.3%) 6(3%) 2(7.1%) 0 0.369 20(4.7%)
Patients with neurological dysfunction upon discharge (n) 0 2®(1%) 11(39.3%) 0.000 13(3.1%)
①There is statistically significant difference between general group and the other 3 groups but no difference in comparison to the other 3 groups. ②There is
statistically significant difference between all groups. ③There is no difference between general groups and severely group or critically group and fatal group, but
there is significant difference between each one of the former and the latter two groups. # There was no repeat counting in calculating the distribution of
disease types. When neurogenic pulmonary edema or shock and brain stem encephalitis coexisted in the same patient, the former was counted. When
neurogenic shock and pulmonary edema coexisted, pulmonary edema was counted. §The denominator of the fraction represents the cases examined, whereas
the numerator represents the number of patients with this abnormality. ¤Among the 5 fatal cases, 2 died of neurogenic pulmonary edema, 2 died of shock and
1 patient was declared brain-dead
Figure 2 Pathogen distributions in different months.
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(27.9%), and the incidence in patients infected with
other enteroviruses was 1 (5%); the differences among
the 3 groups were significant (p < 0.05). Among the 13
patients with some neurologic dysfunction at discharge,
11 were infected with EV71, which was significantly dif-
ferent from the rates found in the other 2 groups (p <
0.05). The 13 patients with neurologic dysfunction after
treatment in the acute phase included the following: 5
patients with difficulty swallowing or coughing, a ten-
dency to cough, a tendency to salivate and difficulty in
getting rid of sputum; 5 patients with limb movement
dysfunction, 2 of whom had grade-III muscle strength
in both lower extremities and 3 of whom had grade-III
muscle strength in a single limb and 1 patient with
mental decline. After 3 months of mechanical ventila-
tion in the pediatric intensive care unit (PICU), these
patients showed stable vital signs and the presence of
brain function; however, they still did not have regular,
effective, spontaneous respiration. Two of these patients
required prolonged mechanical ventilation and were
transferred to local hospitals for further treatment. The
5 patients who died were infected with EV71; the differ-
ence in pathogen prevalence was significant (p < 0.05),
as shown in Table 2.
The pathogen distribution in the 92 cases of HFMD
patients with nervous system damage is shown in Table
3. Among the 3 groups, there was a significant differ-
ence observed in the prevalence of neurogenic pulmon-
ary edema (p < 0.05). EV71 was the most frequently
detected agent in patients for all the diseases studied.
Compared to CA16 or other enteroviruses, EV71 was
most likely to cause all severe neurological diseases
except for encephalitis. CA16 and other enteroviruses
were the most common agents in encephalitis. EV71-
infected patients had a much higher incidence of clinical
coma or limb movement disorder than the other 2
groups; these differences were significant (p < 0.05).
Although EV71 infection was more likely to cause
abnormal numbers of white blood cells in cerebrospinal
fluid (CSF), there was no significant difference among
the 3 groups (p > 0.05). In contrast to the results in
Table 2, there were no significant differences among the
different viruses in the frequency of neurological
damage leading to dysfunction upon discharge or death
p > 0.05.
Discussion
Enterovirus infection is prevalent worldwide and usually
prevales in warm weather, especially in summer and
autumn, when it is associated with an increase in central
nervous system infection [18]. In our study, the first
patients with severe neurological impairment were
admitted in April, and additional patients followed in
June, July and August. Cases peaked in August and
decreased afterward [19,20]. This seasonal distribution
coincides with the trend in recent 3 years observed in
Liaoning Province. In southern China, in Guangdong
and Shandong, the flow of patients with severe symp-
toms started in March and April, possibly because of
the warmer southern climate. Similar to recent studies
Table 2 Comparison of the clinical data from patients with different enteroviruses
EV71 CA16 OE p value Total
Total (n) 89 68 20 177
Gender (Male, n) 52(58.4%) 38(55.9%) 14(70%) 0.528 104(58.8%)
Age*(Years) 2.382 ± 2.102 2.588 ± 1.860 1.875 ± 1.146 0.347
Region (from countryside, n) 57(64%) 41(60.3%) 13(65%) 0.868 111(62.3%)
Time from onset to hospitalization (d)② 3.258 ± 1.176 4 ± 1.258 3.6 ± 1.353 0.001
Duration of hospitalization (d) 14.337 ± 17.796 9.338 ± 3.366 8.1 ± 3.354 0.182
WBC > 12 × 109 (n) 51(57.3%) 32(47.1%) 11(55%) 0.437 94(530.1%)
CRP > 8 mg/dl (n) 4(4.5%) 3(4.4%) 1(5%) 0.994 8(4.5%)
Duration of initial fever(d) 6.034 ± 3.131 5.706 ± 1.684 5.45 ± 1.468 0.547
Highest fever temperature (°C)③ 39.144 ± 0.563 38.919 ± 0.494 38.92 ± 0.618 0.025
Hand or foot rash (n) 81(91%) 67(98.5%) 20(100%) 0.057 168(94.9%)
Oral rash (n) 58(65.2%) 50(73.5%) 15(75%) 0.451 123(69.5%)
Buttock rash (n) 39(43.8%) 28(41.2%) 6(30%) 0.525 73(41.2%)
No rash (n) 3(2.2%) 0 0 0.221 3(1.7%)
Accompanied nervous system damage 65(73%) 19(27.9%) 8(40%) 0.000 92(52%)
Patients with dysfunction upon discharge (n) 11(12.4%) 1(1.5%) 1(5%) 0.030 13(7.3%)
Death (n) 5(7.3%) 0 0 0.030 5(2.8%)
*Patients aged 0-12 months were counted as being 0.5 years of age; patients aged 1-2 years were counted as being 1.5 years of age; patients aged 2-3 years
were counted as being 2.5 years of age, etc. ¤Among the 5 fatal cases, 2 patients died of neurogenic pulmonary edema, 2 died of shock, and 1 was diagnosed
as being brain-dead. ② Statistically significant difference between groups A and B but no difference in comparison to the other 2 groups. ③There is statistically
significant difference between group A and groups B and C but no difference in comparison to the other 2 groups
Xu et al. Virology Journal 2012, 9:8
http://www.virologyj.com/content/9/1/8
Page 4 of 9
[21], males account for 64.3% of all patients in this
study and are prone to severe symptoms. Although
some studies reported that aged 4-9 years [22] or 5-10
years [23] may be the most susceptive period, we found,
as in many studies [13] that patients under 5 years of
age are at the highest risk, with most severe symptoms
in the youngest patients. Rural preference is also
observed, especially in patients with the most severe
symptoms. We cautiously attribute this to the large
rural population of China, as rural areas have poorer
health care conditions and poorer environmental health;
To make things worse, the water sanitation standard is
low in rural China [24] (Table 1).
Among the 6,027 patients, 423 (7.0%) were hospita-
lized; the major pathogen in HFMD has been reported
to be CA16, which generally causes mild and self-limited
symptoms. The main pathogens in Beijing in 2009 were
CA16 (49.4%) and EV71 (36.4%) [25]. In recent out-
breaks, however, EV71 infection has been the major
cause of HFMD [26,27]. This virus was also the major
pathogen in this study. EV71 accounted for 85 infections
(45.0%), and CA16 accounted for 71 (36%). In severely
ill and critically ill patients, EV71 accounts for an even
higher proportion. It was responsible for all the 5
deaths, although the case number is limited. This distri-
bution is different from previous observations (Table 1),
possibly because the studied population includes only
hospitalized patients with relatively severe symptoms.
EV71 caused neurologic damage in 65 patients, (70.7%),
and CA16 was the pathogen in 19 patients (20.7%). It
was possible that in Shenyang in 2010, EV71 was the
major infective agent, but there is currently no official
evidence to support this claim.
A different distribution of the gene in the population
might explain why, in the past decade, EV71 has mainly
caused disease in Taiwan, Malaysia, mainland China,
Japan and other Asia-Pacific regions [28]. Taiwan
researchers found that the histocompatibility leukocyte
antigen (HLA)-A33 gene was correlated with susceptibil-
ity to virus infection and HLA-A2 was closely correlated
with the occurrence of pulmonary edema. EV71 is neu-
rotropic and can directly cause central neurological
impairment; the virus replicates at the lesion site
[29,30]. EV71 VP capsid proteins can bind to ornithine
decarboxylase, gene-trap ankyrin repeats (GTARs) and
other proteins expressed in neurons in the brain and
cause cell injury [31]. Besides, it activates various cyto-
kine pathways or bypasses signaling pathways to induce
apoptosis or necrosis [32-35]. Studies have shown that
in a mouse model, IgG antibodies generated during
EV71 infection can pass the blood-brain barrier and
cross-react with host brain tissue [36].
Other enteroviruses, such as ECHO7, ECHO14, the
CVB group, CA6 and CA10, can all cause pediatric
HFMD [37-39]. Other major enteroviruses in our stu-
dies include ECHO14, CVB and CVA10. In recent years,
Table 3 Data analysis of the clinical neurological damage caused by different pathogens
EV71 CA16 OE p value Total
Total (n) 65(70.7%) 19(20.7%) 8(8.7%) 92
Encephalitis (n)# 39(60%) 16(82.4%) 6(75%) 0.125 61(66.3%)
Acute flaccid paralysis (n)# 2(3%) 1(5.3%) 0 0.772 3(3.3%)
Brainstem encephalitis (n)# 8(12.3%) 2(1.1%) 0 0.572 10(10.9%)
Neurogenic pulmonary edema (n)# 11(16.9%) 0 1(12.5%) 0.047 11(12%)
Neurologic shock (n)# 5(7.7%) 0 1(12.5%) 0.215 6(6.5%)
Limb shaking (n) 51(78.5%) 15(78.9%) 6(75%) 0.973 72(78.3%)
Convulsion (n) 21(32.3%) 4(21.1%) 2(25%) 0.613 27(29.3%)
Vomiting (n) 42(64.6%) 16(84.2%) 7(87.5%) 0.141 65(70.7%)
Fatigue (n) 47(72.3%) 17(89.5%) 5(62.5%) 0.219 69(75%)
Coma (n) 24(36.9%) 2(10.5%) 1(12.5%) 0.046 27(29.3%)
Limb movement disorder (n) 34(52.3%) 3(15.8%) 2(25%) 0.010 39(42.4%)
Urinary retention (n) 31(47.7%) 6(31.6%) 2(25%) 0.266 39(42.4%)
CSFWBC > 10 × 106/L (n)§ 21/44(47.7%) 8/14(57.1%) 3/6(50%) 0.828 25/64(39.1%)
CSFPro ≥ 0.5 g/L (n)§ 15/44(34.1%) 5/14(35.7%) 2/6(33.3%) 0.992 22/64(34.4%)
Ambulatory EEG abnormality (n)§ 17/32(53.1%) 4/13(30.8%) 1/5(20%) 0.205 22/50(44%)
Head MRI abnormality (n)§ 13/32(40.6%) 5/15(33.3%) 2/6(33.3%) 0.685 20/53(37.7%)
Patients with dysfunction upon discharge (n) 11(16.9%) 1(5.3%) 1(12.5%) 0.435 13(14.1%)
Death (n)¤ 5(7.7%) 0 0 0.333 5(5.4%)
# There was no repeat counting in calculating the distribution of disease types. When neurogenic pulmonary edema or shock and brain stem encephalitis
coexisted in the same patient, the former was counted. When neurogenic shock and pulmonary edema coexisted, pulmonary edema was counted. §The
denominator of the fraction represents the cases examined, whereas the numerator represents the number of patients with this abnormality. ¤Among the 5 fatal
cases, 2 died of neurogenic pulmonary edema, 2 died of shock and 1 patient was declared brain-dead
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these viruses have shown an increasing trend as causes
of HFMD; in particular, CVA6 and CVA 10 have
recently emerged as pathogens of HFMD outbreaks in
other countries, including Singapore and Finland [40,41]
With the exception of ECHO14, the echovirus serotypes
identified and the CVB group viruses, including CVB3,
CVB4 and CVB5, have been previously associated with
cases of HFMD [18,42].
The expression of the scavenger receptor class B,
Member 2 (SCARB2) receptor protein can facilitate
virus propagation in cells that normally are not suscepti-
ble to EV71 infection and also cause pathogenesis in
these cells. CA16 can infect cells through the same
pathway, but most other enteroviruses in group A do
not depend on this ligand [43,44]. CA16 is generally
associated with fewer neurologic complications, with the
exception of infrequent cases of aseptic meningitis [45].
Neurological injuries caused by CA16 are relatively mild
and deaths are especially rare. Therefore, the disease has
attracted little attention [46,47]. However, we find that
CA16 can also cause considerable neurological impair-
ment. Although most affected patients had mild symp-
toms, three experienced severe, complicated nervous
system injuries, two experienced brain-stem encephalitis
and one suffered from AFP. The mechanism of patho-
genesis, however, is not yet known, and it is not known
whether neurons have receptors for EV71.
Neurogenic shock and neurogenic pulmonary edema
occur simultaneously under most conditions and are
highly dangerous; even if the circulation and lung func-
tion recover, brain and peripheral nervous function are
more difficult to protect, and all of the 9 deaths in this
study had neurogenic shock and/or neurogenic pulmon-
ary edema. Death frequently occurs during the early
stage of the disease (1st week), and brain death could
occur even after circulation and respiratory functions
are restored Even if the rescue is successful, the clinical
recovery for these child patients is very slow. Some
require prolonged mechanical ventilation to allow time
for recovery; others require even longer ventilation to
recover body movement and cranial nerve (glossophar-
yngeal nerve, vagus nerve or hypoglossal nerve) func-
tions. Brainstem injury has long been considered a
major cause of pulmonary edema [21,48]. In previous
studies, however, pulmonary edema did not occur in
monkeys with brainstem injury; therefore, other
mechanisms may lead to EV71-related pulmonary
edema [49]. Recent studies show that increased levels of
the inflammatory cytokines interleukin-l (IL-1), interleu-
kin-6 (IL-6), interleukin 10 (IL-10), interleukin 13 (IL-
13), interferon g (IFN-g) and tumor necrosis factor a
(TNF-a) and immune suppression of CD3 and CD4 T-
cells and natural killer (NK) cells are related to pulmon-
ary edema [50]. The release of various inflammatory
factors stimulates a radical inflammatory response and
the release of catecholamines, causing an increased
release of interleukin-8 (IL-8) and changes in pulmonary
capillary permeability, leading to pulmonary edema
[5,51,52].
The distribution of rash in HFMD patients infected by
various viruses in this study showed no statistically sig-
nificant differences, but three EV71-infected patients did
not have any rash, and similar cases, as have been pre-
viously reported [3,53]. Convulsions, coma, body move-
ment dysfunction and urinary retention mainly occur in
EV71-infected patients because of their severe nervous
system injuries. Cerebrospinal fluid, EEG and head MRI
abnormalities also mainly occur in this group of
patients. While this difference is not statistically signifi-
cant, the limited sample size is probably to blame. As
mentioned above, the disease progress rapidly, and
apparent nervous system injury was observed at
approximately 3 days. Body temperature rises to > 39.1°
C accompanied by convulsions, coma, limb movement
disorder and severe complications such as neurogenic
shock or neurogenic pulmonary edema. For patients
with no rash, EV71 infection should be strongly sus-
pected (Tables 2, 3).
Conclusion
The risk factors of life-threatening cases in hospitalized
HFMD patients include young age, high fever, male gen-
der and EV71 infection. HFMD patients infected with
EV71 have a faster disease progression, higher fever and
a higher incidence of limb movement disorder, coma,
neurological damage, neurogenic pulmonary edema and
death. Patients with neurological complications are
prone to worse outcome and severe sequela. Generally,
in HFMD patients, the symptoms of neurological
damage caused by CA16 or other enteroviral infections
are relatively mild, and the patients’ prognoses are bet-
ter. Severely ill patients, especially the critically and
fatally ill patients are mostly infected by EV71; Nonethe-
less CA16 and other enteroviruses can also cause severe
neurological symptoms in HFMD.
Materials and methods
An outbreak of pediatric hand, foot and mouth disease
occurred in Liaoning Province of China in 2010.
Patients with severe symptoms were hospitalized, and
those in grave condition were treated in the pediatric
intensive care unit (PICU). A retrospective analysis of
this outbreak was conducted using general clinical data
and data on clinical manifestations. Our study has been
approved by the institutional review board of China
Medical University. Pathogen test were carried out after
informing and gaining permission from the patients’
parents. The study focused on neurological
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complications and findings related to the pathogens and
their correlations with HFMD in patients admitted to
Shengjing Hospital of China Medical University between
January 1st and December 31st 2010.
Grouping
The hospitalized patients were grouped by disease severity.
A general patient was diagnosed with HFMD, and accom-
panied any one of the following symptoms: 1, lethargy,
irritability or other behavioral signs of infection; 2, pneu-
monia and an increase in myocardial enzymes (particularly
troponin, CPK-MB and their isozymes); 3, more than two
incidences of vomiting accompanied by limb shaking;4, no
improvement in symptoms 3 days after outpatient treat-
ment or an unstable condition resulting in hospitalization.
Severe group included patients presenting with obvious
symptoms of nervous system involvement in HFMD,
including complicating myoclonus, encephalitis, brain-
stem encephalitis and acute flaccid paralysis in addition to
the basic symptoms of HFMD. The critically ill patients
were those whose treatment was complicated by central
respiratory failure or those who had brain-stem encephali-
tis, acute flaccid paralysis, neurogenic pulmonary edema,
neurogenic shock or other severe symptoms and required
endotracheal intubation and mechanical ventilation. Fatal
patients included patients who died of respiratory and car-
diac arrest and those who suffered brain death during
treatment.
A second grouping was based on the pathogens
detected: group EV71, group CA16 and group OE refer-
ring to patients infected with other enteroviruses.
Diagnosis
HFMD was defined as a febrile illness (temperature >
37.5°C) accompanied by a papulovesicular rash of the
oral mucosa, limb extremities and/or buttocks. Encepha-
litis was defined as persistent fever, altered conscious-
ness, vomiting, limb shaking and convulsions with or
without changes as seen in tests of cerebrospinal fluid
and head imaging. Brainstem encephalitis was defined as
brain-stem injury accompanied by lethargy and cranial
nerve palsy with the clinical manifestations of cerebellar
ataxia in addition to encephalitis. AFP was defined as
the acute onset of loss of motor function in at least 1
skeletal muscle group (usually the limbs) associated with
absent or diminished reflexes in the affected muscle
group(s). Neurogenic pulmonary edema was defined as
having an acute onset with early difficulty in breathing
accompanied by a large amount of bloody, frothy spu-
tum, auscultation of the lungs, high blood pressure,
apparent pulmonary edema detected by chest X-Ray or
bloody sputum drawn into an endotracheal tube. The
term dysfunction is used in reference to patients who,
after acute-phase treatment, still had a decreased ability
to swallow and cough as well as decreased body move-
ment and intelligence or those who had stable vital
signs but lacked regular and effective autonomous
respiration and relied on prolonged mechanical ventila-
tion. All diagnoses of nervous system disease were made
with the support of a pediatric neurologist.
Pathogen detection
Throat swab and/or stool specimens were collected
from each child enrolled in the study. These samples
were transported immediately at 4°C to the Centers for
Disease Control and Prevention (CDC, Shenyang,
China) for the detection of EV71, CA16 and OE using
the enterovirus nucleic acid detection kit (triplex real-
time polymerase chain reaction assay; Guangzhou Daan
Gene Co., Ltd., Guangzhou, China).
Viral RNA was isolated with Trizol reagent (Invitro-
gen, Carlsbad, CA). The cDNA synthesis was performed
using the RNA PCR Kit (AMV) Ver. 3.0 (TaKaRa,
Dalian, China). The 25 μL PCR reaction mixture con-
tained 1× buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 20
pmol forward primer and reverse primer and 20 pmol
fluorescence-labeled probe for each target (see Table 4),
1 U of Taq polymerase and 5 μL of cDNA. Multiplex
real-time PCR was performed on 7,500 Real-Time PCR
System (Applied Biosystems, Foster City, CA) with the
following conditions: 3 min at 94°C followed by 40
cycles at 93°C for 15 s and 55°C for 45 s.
Statistical analysis
Data analysis was conducted using the SPSS 13.0 soft-
ware. Discrete variables are expressed as counts
Table 4 Nucleotide sequences of the specific primers and TaqMan probes used in this study











The analysis of real-time PCR data: the threshold cycle (CT) value for each sample was calculated by determining the point at which the fluorescence exceeded
the threshold limit, and the cut off was 35.1 determined by the ROC curve. The results of negative, positive and quality controls which were included in each
experiment were within the normal range.
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(percentages), and continuous variables are expressed as
means ± standard deviation (SD). Differences in the
demographic and clinical characteristics of the patient
groups were assessed using the chi-square test for cate-
gorical variables. As the data showed a normal distribu-
tion, One-way ANOVA was adopted to analyze inter-
subgroup differences. As the data did not show normal
distribution, Kruskal Wallis Test was adopted to analyze
inter-subgroup differences. p ≤ 0.05 was considered sta-
tistically significant.
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